Accepted for Publication: February 7, 2022.
Published Online: April 21, 2022. doi:10.1001/jamaoncol.2022.0752
Correction: This article was corrected on July 21, 2022, to fix errors in the byline and affiliations.
Corresponding Author: Qamar J. Khan, MD, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS 66210 (qkhan@kumc.edu).
Author Contributions: Dr Khan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Sharma and Godwin contributed equally as senior authors.
Concept and design: Khan, Bivona, Zhang, Nelson, Williamson, Sun, Streeter, Mcguirk, Hoffmann, Sharma, Godwin.
Acquisition, analysis, or interpretation of data: Khan, Martin, Zhang, Liu, He, Li, Nelson, Williamson, Doolittle, Sun, Mudaranthakam, Mcguirk, Al-Rajabi, Kasi, Parikh, Zhong, Mitchell, Pessetto, Pathak, Ghosh, LaFaver, Sharma.
Drafting of the manuscript: Khan, Bivona, Mudaranthakam, Mcguirk, Al-Rajabi, Sharma, Godwin.
Critical revision of the manuscript for important intellectual content: Khan, Bivona, Martin, Zhang, Liu, He, Li, Nelson, Williamson, Doolittle, Sun, Mudaranthakam, Streeter, Mcguirk, Hoffmann, Kasi, Parikh, Zhong, Mitchell, Pessetto, Pathak, Ghosh, LaFaver, Sharma, Godwin.
Statistical analysis: Zhang, Liu, He, Nelson, Mudaranthakam, Zhong.
Obtained funding: Khan, Doolittle, Sun, Streeter, Mcguirk, Sharma, Godwin.
Administrative, technical, or material support: Khan, Bivona, Martin, Zhang, Li, Nelson, Sun, Mudaranthakam, Streeter, Mcguirk, Kasi, Parikh, Zhong, Mitchell, Pessetto, Ghosh, LaFaver, Sharma, Godwin.
Supervision: Khan, Bivona, Mudaranthakam, Streeter, Mcguirk, Pessetto, LaFaver, Sharma, Godwin.
Conflict of Interest Disclosures: Dr Zhang reported personal fees from AstraZeneca as a speaker or consultant, grants from AstraZeneca as a principal investigator (PI), personal fees from Bayer as a consultant, grants from Biodesix as a PI, personal fees from Biodesix as a consultant, personal fees from Bristol Myers Squibb as a consultant, personal fees from Cardinal Health as a consultant, personal fees from Daiichi Sankyo as a consultant, personal fees from Hengrui as a consultant, grants from Hengrui as a PI, personal fees from Eli Lilly as a consultant, grants from Mirati as a PI, personal fees from Mirati as a consultant, personal fees from Nexus Health as a consultant, grants from Novartis as a PI, personal fees from Novartis as a consultant, personal fees from Novocure as a consultant, personal fees from Regeneron as a speaker or consultant, personal fees from Sanofi as a speaker or consultant, grants from Genentech as a PI, grants from AbbVie as a PI, grants from BeiGene as a PI, and grants from Nilogen as a PI outside the submitted work. Dr Mcguirk reported personal fees from Kite Pharma, personal fees from Bristol Myers Squibb, personal fees from BioMed, personal fees from GCO, personal fees from G-Med, and personal fees from Mid-America Cancer outside the submitted work. Dr Al-Rajabi reported grants from Bayer for institutional support, grants from NuCana for institutional support, grants from Incyte for institutional support, grants from AstraZeneca for institutional support, grants from Eureka Therapeutics for institutional support, grants from Merck for institutional support, grants from Pfizer for institutional support, holding stockk in Seattle Genetics and Actinium Pharmaceuticals Inc outside the submitted work. Dr Hoffmann reported personal fees from Janssen, personal fees from Pharmacyclics, personal fees from AstraZeneca, personal fees from TG Therapeutics, personal fees from Novartis, and personal fees from BeiGene outside the submitted work. Dr Godwin reported personal fees from Sinochips Diagnostics as the cofounder during the conduct of the study. No other disclosures were reported.
Funding/Support: This work was supported in part by The University of Kansas Cancer Center and the Investigator Initiated Steering Committee, a grant from the National Institute of General Medical Sciences (P20 GM130423), and The University of Kansas Cancer Center Support Grant from the National Cancer Institute (P30 CA168524). Dr Godwin is the Chancellors Distinguished Chair in Biomedical Sciences Endowed.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge staff members of The University of Kansas Cancer Center’s Biospecimen Repository Core Facility, including Michele Park and Lauren Dimartino, who are supported, in part, by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA168524, and the staff members of Sinochips Diagnostics.
1.Bakouny
Z , Hawley
JE , Choueiri
TK ,
et al. COVID-19 and cancer: current challenges and perspectives.
Cancer Cell. 2020;38(5):629-646.
PubMedGoogle ScholarCrossref 2.Al-Shamsi
HO , Alhazzani
W , Alhuraiji
A ,
et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group.
Oncologist. 2020;25(6):e936-e945.
PubMedGoogle ScholarCrossref 3.Sharma
A , Bhatt
NS , St Martin
A ,
et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
Lancet Haematol. 2021;8(3):e185-e193.
PubMedGoogle ScholarCrossref 4.Boyarsky
BJ , Werbel
WA , Avery
RK ,
et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients.
JAMA. 2021;325(17):1784-1786.
PubMedGoogle ScholarCrossref 5.Hall
VG , Ferreira
VH , Ku
T ,
et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients.
N Engl J Med. 2021;385(13):1244-1246.
PubMedGoogle ScholarCrossref 6.Mueller
T . Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer.
Clin Chim Acta. 2021;518:9-16.
PubMedGoogle ScholarCrossref 7.Terpos
E , Trougakos
IP , Apostolakou
F ,
et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
Am J Hematol. 2021;96(7):E257-E259.
PubMedGoogle ScholarCrossref 8.Turner
JS , O’Halloran
JA , Kalaidina
E ,
et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Nature. 2021;596(7870):109-113.
PubMedGoogle ScholarCrossref 9.Schmidt
AL , Labaki
C , Hsu
CY ,
et al; COVID-19 and Cancer Consortium. COVID-19 vaccination and breakthrough infections in patients with cancer.
Ann Oncol. 2022;33(3):340-346.
PubMedGoogle ScholarCrossref 10.Bergwerk
M , Gonen
T , Lustig
Y ,
et al. Covid-19 breakthrough infections in vaccinated health care workers.
N Engl J Med. 2021;385(16):1474-1484.
PubMedGoogle ScholarCrossref 11.Gilbert
PB , Montefiori
DC , McDermott
A ,
et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial.
medRxiv. Preprint posted online January 1, 2021.
Google Scholar 12.Khoury
DS , Cromer
D , Reynaldi
A ,
et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Nat Med. 2021;27(7):1205-1211.
PubMedGoogle ScholarCrossref 13.McMahan
K , Yu
J , Mercado
NB ,
et al. Correlates of protection against SARS-CoV-2 in rhesus macaques.
Nature. 2021;590(7847):630-634.
PubMedGoogle ScholarCrossref